2. UroToday Home
  3. Trials in Progress

Trials in Progress

MEVPRO-3: Phase III Study of Mevrometostat + Enzalutamide (versus placebo plus enzalutamide) in ARPI-naïve mCSPC

Trials in Progress
Videos

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) With Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3)

  • Condition: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
  • Study ID: NCT07028853
View Trial
Conference Coverage
Conference Highlights Written by Physician Scientists
Presented by Neeraj Agarwal, MD, FASCO
Neeraj Agarwal, MD, FASCO, discussed MEVPRO-3, a phase III trial of mevrometostat + enzalutamide versus placebo + enzalutamide in mCSPC. Enhancer of zeste homolog 2 (EZH2) enzymatic activity plays a crucial role in prostate cancer progression. Mevrometostat, an oral potent and selective EZH2 inhibitor, may synergize with androgen receptor pathway inhibitors to delay androgen receptor pathway inhibitor resistance.
Presented by Neal D. Shore, MD, FACS
The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Neal D. Shore, MD, FACS, discussing patient-reported outcomes in a randomized phase 1 study of mevrometostat + enzalutamide versus enzalutamide alone in patients with metastatic castration‑resistant prostate cancer (mCRPC).
Presented by Nobuaki Matsubara, MD
The 2025 ASCO Annual Meeting held in Chicago, IL was host to the Poster Session: Genitourinary Cancer - Prostate, Testicular, and Penile Cancer. Dr. Nobuaki Matsubara presented Poster 5046: Safety and pharmacokinetics of mevrometostat in combination with enzalutamide in patients with mCRPC.